NorthWest Biotherapeutics Inc (NWBO)

[rocky66]

Your thoughts on the SOC in the future.
If the new SOC for GBM will be DCVax-L + poly-ICLC, does that not move the bar higher in current and future Clinical Trails? Are we not looking at an mOS that is much higher to achieve?
What will this do to the ongoing trials in process right now and future Trials?
What will happen to the enormous amount of ECA data with Chemo as the SOC to compare results of a trial to? Will it all be obsolete with the new SOC for GBM being DCVax-L + poly-ICLC?
This seems to have the potential to be very disruptive to the Bio industry's future.
Even today, pre-approval, we are comparing ongoing competing Clinical trials to DCVax-L TLD results. TIA